Aegis Capital Corp. in a Follow-on Public Offering
Blank Rome represented Aegis Capital Corp. in a $14 million follow-on public offering of common stock of Advaxis, Inc., a clinical-stage biotechnology company developing multiple cancer immunotherapies. The transaction closed on March 28, 2014.